We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Avacta

AVA6000 set for third dose escalation stage

Lighthouse | 30 June 2022

Redx Pharma

All the ingredients for success now in place

Update | 29 June 2022

Redx Pharma

Jazz Pharmaceuticals $5m milestone triggered

Lighthouse | 15 June 2022

Scancell

First Moditope oncology vaccine enters the clinic

Lighthouse | 13 June 2022

Redx Pharma

£34.3m raise extends runway through key data points

Lighthouse | 07 June 2022

Arecor Therapeutics

AT278 hits the sweet spot

Update | 31 May 2022

ANGLE

Parsortix FDA clearance marks a key transition point

Lighthouse | 26 May 2022

Futura Medical

Major MED3000 deal for Europe with Cooper Health

Lighthouse | 23 May 2022

MaxCyte

Robust Cell Therapy performance lifts FY22 guidance

Lighthouse | 23 May 2022

ANGLE

FY21 results: prepared for commercial success

Lighthouse | 28 April 2022
1 2 3 4 5 6 7 8 9 10 >
311 results found.